Imeka Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Imeka General Information
Description
Developer of a brain imaging system designed to offer insights into neuroinflammation, demyelination and axonal loss. The company's technology offers MRI high-standing structure as well as a PET (positron emission tomography) or SPECT (single-photon emission computed tomography) preclinical cardiac analysis service, enabling pharmaceutical companies to understand brain connectivity specifically white matter imaging.
Contact Information
Website
www.imeka.caCorporate Office
- 195, Belvédère Nord
- Bureau 201
- Sherbrooke, Quebec J1H 4A7
- Canada
Corporate Office
- 195, Belvédère Nord
- Bureau 201
- Sherbrooke, Quebec J1H 4A7
- Canada
Imeka Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 24-Oct-2023 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Jan-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 12-Dec-2017 | Completed | Generating Revenue | |||
| 5. Debt - General | 01-Apr-2017 | Completed | Generating Revenue | |||
| 4. Early Stage VC | Completed | Startup | ||||
| 3. Accelerator/Incubator | 01-Jan-2015 | Completed | Startup | |||
| 2. Debt - General | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Imeka Patents
Imeka Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260112031-A1 | Harmonization of diffusion magnetic resonance imaging | Pending | 21-Oct-2024 | ||
| WO-2026088076-A1 | Harmonization of diffusion magnetic resonance imaging | Pending | 21-Oct-2024 | ||
| US-20250384556-A1 | Automatic quality control of image diffusion processing | Pending | 17-Jun-2024 | ||
| US-12573498-B2 | Determination of white-matter neurodegenerative disease biomarkers | Active | 16-Jul-2021 | ||
| US-20230022257-A1 | Determination of white-matter neurodegenerative disease biomarkers | Active | 16-Jul-2021 | G16H30/40 |
Imeka Signals
Imeka Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alzheimers Drug Discovery Foundation | Not-For-Profit Venture Capital | Minority | ||
| Creative Destruction Lab | Accelerator/Incubator | |||
| Canada Economic Development for Quebec Regions | Government | Minority | ||
| Desjardins Capital | PE/Buyout | Minority | ||
| Fonds Innovexport | Venture Capital | Minority |
Imeka FAQs
-
When was Imeka founded?
Imeka was founded in 2011.
-
Where is Imeka headquartered?
Imeka is headquartered in Sherbrooke, Canada.
-
What is the size of Imeka?
Imeka has 22 total employees.
-
What industry is Imeka in?
Imeka’s primary industry is Diagnostic Equipment.
-
Is Imeka a private or public company?
Imeka is a Private company.
-
What is Imeka’s current revenue?
The current revenue for Imeka is .
-
How much funding has Imeka raised over time?
Imeka has raised $1.55M.
-
Who are Imeka’s investors?
Alzheimers Drug Discovery Foundation, Creative Destruction Lab, Canada Economic Development for Quebec Regions, Desjardins Capital, and Fonds Innovexport are 5 of 7 investors who have invested in Imeka.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process